{"entity":{"id":"nct07087054","kind":"trial","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","aka":[],"tldr":"A phase 3 trial of Paltusotine in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by Crinetics Pharmaceuticals Inc., now recruiting.","summary":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen is a phase 3 interventional study registered as NCT07087054 by Crinetics Pharmaceuticals Inc., with 141 participants planned, started 2025-11-19 and due to reach its primary completion in 2027-08. Interventions recorded: Paltusotine and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07087054","url":"https://clinicaltrials.gov/study/NCT07087054"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["crinetics-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07087054","phase":"3","setting":"A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors","sponsor":"Crinetics Pharmaceuticals Inc.","enrolled":141,"outcomes":[]},"route":"/trials/nct07087054/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","route":"/companies/crinetics-pharmaceuticals/"}]}}